Pay in 4 interest-free payments of $5.57 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
While the PARS1 inhibitor halofuginone exhibited toxicity, its optimized derivative DWN12088 demonstrated improved safety and efficacy in preclinical models and is currently under clinical investigation for IPF [143]
Recent literature is cited on patients undergoing upper endoscopy with no predictability regarding holding the drug and finding retained gastric contents
No Competition When supply is scarce, prices tend to rise
The STEP 5 trial followed participants for 104 weeks and found 15.2% weight loss suggesting benefits sustain with continued use (Garvey et al., Lancet Diabetes & Endocrinology, 2022)
US$ 24.97
US$ 22.76
US$ 29.01
US$ 23.75
US$ 22.44
/product/42/083935/1.jpg?0295)
US$ 29.96
US$ 26.53
US$ 26.22
